Targeted Genetics Enhances Patent Portfolio Related to AAV Serotype 1 (RedNova)

Targeted Genetics Enhances Patent Portfolio Related to AAV Serotype 1 (RedNova)
Targeted Genetics Corporation (Nasdaq:TGEN) today announced the issuance of a new patent that further strengthens the company’s leadership in developing adeno-associated virus (AAV)-based therapies. U.S.